A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects with Type 2 Diabetes Mellitus
Latest Information Update: 01 Aug 2022
At a glance
- Drugs P 1736 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Jun 2011 New trial record